CRMD NASDAQ
CorMedix Inc.
1W: +5.7%
1M: +1.4%
3M: +11.3%
YTD: -34.2%
1Y: -28.4%
3Y: +153.2%
5Y: +64.3%
$8.00
+0.06 (+0.76%)
Weekly Expected Move ±4.8%
$7
$7
$8
$8
$9
Credit Risk of going bust: higher than 65% of companies Debt: 18.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.22 (down 97%), CorMedix Inc. would be worth roughly what it owes.
Total debt $145.2M against a stock market value of $623.6M.
Distance to default 3.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $72.6M (short-term plus half of long-term), stock volatility 62.0%; Altman Z'' 4.41. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.22 (down 97%), CorMedix Inc. would be worth roughly what it owes.
Total debt $145.2M against a stock market value of $623.6M.
Distance to default 3.84 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $72.6M (short-term plus half of long-term), stock volatility 62.0%; Altman Z'' 4.41. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (83)
Healthcare stocks with strong revenue growth and attractive valuations
Cormedix gets FDA priority review for Rezzayo label expansion
Actinium Pharmaceuticals names former CorMedix executive as CFO
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet
Bank of New York Mellon Corp Takes Position in CorMedix Inc $CRMD
CorMedix (CRMD) Upgraded to Buy: Here's Why
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
CorMedix Inc. Q2 2026 Earnings Call Summary
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates
CorMedix Inc. (CRMD) revenue jumps as Melinta deal boosts Q2 2026 profit - stocktitan.net
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix Inc. (CRMD) Reports Q1 2026 Results
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix Inc. Q1 2026 Earnings Call Summary
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
12 Health Care Stocks Moving In Thursday's Pre-Market Session
[10-Q] CorMedix Inc. Quarterly Earnings Report - Stock Titan
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix Eyes $2 Billion Market With Encouraging Data From Fungal Infection Study
CorMedix to Participate in Needham Virtual Healthcare Conference
Phocas Financial Corp. Takes $1.99 Million Position in CorMedix Inc $CRMD
Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?
Assenagon Asset Management S.A. Increases Stock Holdings in CorMedix Inc $CRMD
Do Options Traders Know Something About CorMedix Stock We Don't?
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration
CorMedix (CRMD) Q4 2025 Earnings Call Transcript
CorMedix nears an 11-month low after earnings miss
CorMedix (CRMD) Lags Q4 Earnings Estimates
Cormedix Earnings Review: Q4 Summary
CorMedix reports mixed Q4 results; reaffirms FY26 outlook
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Earnings Scheduled For March 5, 2026
Here are the major earnings before the open Thursday
CorMedix Q4 2025 Earnings Preview
Cormedix Earnings Preview
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
Lowest Quant ranked small-cap stocks with positive EPS surprises
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet?
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings?
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
CorMedix Inc. (CRMD) Analyst/Investor Day Transcript
CorMedix to Participate in Upcoming Investor Conferences
CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside
CorMedix (NASDAQ:CRMD) to Buyback $75.00 million in Outstanding Stock
CorMedix Therapeutics Announces Share Repurchase Program
CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
Hussman Strategic Advisors Inc. Purchases 252,000 Shares of CorMedix Inc $CRMD
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Are Investors Undervaluing CorMedix (CRMD) Right Now?
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Why is CorMedix stock crashing today: is it worth buying on the dip?
CorMedix Therapeutics Announces Leadership and Board Updates
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
Why CorMedix Could be the Biopharma Name to Watch Early in 2026
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?
CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?